131I-Radiopharmaceutical
Iodine-131 radiopharmaceuticals are a form of targeted therapy using the radioisotope 131I, widely employed in cancer treatment, particularly for thyroid cancer and other tumors. This approach involves the release of localized radiation to directly destroy tumor cells. Alfa Cytology offers research and development services for 131I radiopharmaceuticals, focusing on creating highly effective and targeted therapies that optimize dose distribution and enhance therapeutic efficacy in tumor treatment.
Overview of 131I-Radiopharmaceutical
Iodine-131 radiopharmaceuticals leverage the radioactive properties of 131I for medical treatment, particularly in thyroid cancer. This isotope emits β particles and γ rays, effectively targeting tumor cells by damaging their DNA and inhibiting growth. Unlike traditional chemotherapy, 131I provides localized radiation therapy via oral or intravenous administration, minimizing damage to healthy tissues. It involves binding 131I to molecules that specifically target cancer cell receptors, making it ideal for treating thyroid cancer, certain lymphomas, and localized or metastatic tumors.
![The prediction of radiosynthesis reaction of [131I] I-AM.](https://www.rdcthera.com/wp-content/themes/rdc/upload/2-1-1-1-7-131i-radiopharmaceutical-1.jpg)
Fig 1. The prediction of radiosynthesis reaction of [131I] I-AM. (NURHIDAYAH W, et al., 2023)
Distinctive Features of 131I-Radiopharmaceutical
131I is a radioisotope that emits both β particles and γ rays. The beta particles, although of low energy, are effective in penetrating tissues to destroy the DNA of cancer cells, aiding in targeted cancer treatment.
131I exhibits innate targeting capabilities, being selectively absorbed by thyroid tissues and certain types of tumor cells. This makes it particularly effective for treating conditions such as thyroid cancer, leveraging its natural affinity for these tissues.
With a half-life of approximately 8 days, 131I provides a balanced therapeutic window. It continues to emit radiation long enough to be effective in treatment while minimizing the risks of prolonged radiation exposure, thereby enhancing patient safety.
Our Services
Alfa Cytology is committed to developing advanced 131I radiopharmaceuticals that offer innovative targeted therapeutic solutions to optimize dose distribution and enhance oncology outcomes. Our R&D services focus on precisely formulating highly effective radiopharmaceuticals for targeted cancer treatment, ensuring minimal damage to healthy tissues.
Antibodies
Alfa Cytology labels antibodies with 131I to facilitate in vivo distribution, localization, and immunoimaging studies.
Nucleic Acids
131I labeling of nucleic acids enables tracking of transcription and translation processes in cells, and supports the study of biological phenomena such as gene expression and mutation.
Small Molecule Drugs
131I-labeled small molecule drugs are utilized in radiographic imaging techniques like SPECT to assess drug distribution and metabolism in the body.
Glycans
By labeling sugar molecules with 131I, researchers can investigate metabolic processes, sugar receptor recognition, and glycoprotein interactions on cell membranes. This radiolabeling aids in tracing localization, transport, and mechanisms within cells and tissues.
Peptides
Alfa Cytology labels peptides, particularly those targeting specific receptors, with 131I. These highly targeted peptides enhance the precision of radiotherapy and diagnostics by specifically binding to certain cells or tissues.
Cellular and Extracellular Matrix Components
Alfa Cytology uses 131I to label proteins on cell membranes or in extracellular matrix components, such as glycosaminoglycans and collagen. This labeling supports studies on cell migration, proliferation, differentiation, and cell-cell interactions.
Imaging Services for 131I-Radiopharmaceutical
Alfa Cytology offers 131I radiopharmaceutical imaging services that leverage the radiological properties of 131I to deliver precise molecular imaging, facilitating the early diagnosis and monitoring of tumors, inflammation, and various other diseases.
With a top-notch interdisciplinary research team comprising experts in molecular biology, chemistry, and pharmacology, Alfa Cytology provides a comprehensive one-stop solution for the development of 131I radiopharmaceuticals, from target identification to clinical-ready production. For any questions or additional information, please don't hesitate to contact us; we're here to support your innovative research needs.
Reference
- NURHIDAYAH W, WIDYASARI E M, DARUWATI I, et al. Radiosynthesis, Stability, Lipophilicity, and Cellular Uptake Evaluations of [(131)I]Iodine-α-Mangostin for Breast Cancer Diagnosis and Therapy [J]. International journal of molecular sciences, 2023, 24(10).
For research use only. Not intended for any clinical use.
Related Service
